Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 107 results for thyroid

  1. Percutaneous Laser Ablation (PLA) for benign thyroid nodules

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Minimally invasive video-assisted thyroidectomy (IPG499)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

    Interventional procedures guidance
    Published
    23 August 2014
    View recommendations

    Sections for IPG499

  3. What is the clinical and cost effectiveness of percutaneous thermal ablation for benign thyroid nodules?

    for benign thyroid nodules? Any explanatory notes(if applicable) Source guidance details Comes from guidance Thyroid...

    Research recommendation
    Published
    10 February 2020

  4. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who...

    Research recommendation
    Published
    6 January 2023

  5. Bipolar, schizophrenia and other psychoses: target organ damage (IND86)

    This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21

    General practice indicators suitable for use outside of QOF
    Last updated
    8 August 2019

  6. Diabetes: thyroid disease screening (children)

    This indicator has been updated and replaced by NICE indicator 312.

    Published
    1 August 2016

  7. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

    NICE guideline
    Published
    2 September 2015
    View recommendations

    Sections for NG20

  8. Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?

    surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness...

    Research recommendation
    Published
    6 January 2023

  9. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    6 January 2023

  10. Duration of follow up: What is the clinical and cost effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated?

    effectiveness for different durations of follow up for people with differentiated thyroid cancer who have been treated? Any explanatory...

    Research recommendation
    Published
    6 January 2023

  11. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    Awaiting development Reference number: GID-HST10067 Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  12. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 October 2016
    View quality statements

    Sections for QS134

  13. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  14. Molecular tests: In fine-needle aspiration cytology (FNAC) samples that are adequate but cannot differentiate between benign and malignant samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer?

    samples, what is the clinical and cost effectiveness of molecular testing for thyroid cancer? Any explanatory notes(if applicable) For a...

    Research recommendation
    Published
    6 January 2023

  15. Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive local spread (T2N1), what is the clinical and cost effectiveness of CT, MRI or F-18 FDG PET-CT scanning, with or without ultrasound, as part of a further staging strategy?

    Question Imaging for further staging: For people with differentiated thyroid cancer who have initial ultrasound evidence of extensive...

    Research recommendation
    Published
    6 January 2023